Circulating Serum MicroRNA-130a As a Novel Putative Marker of Extramedullary Myeloma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Sep 22

PMID 26389804

Citations 11

Authors

Lenka Besse

Lenka Sedlarikova

Fedor Kryukov

Jana Nekvindova

Lenka Radova

Ondrej Slaby

Petr Kuglik

Martina Almasi

Miroslav Penka

Marta Krejci

Zdenek Adam

Ludek Pour

Sabina Sevcikova

Roman Hajek

Affiliations

Soon will be listed here.

Abstract

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without such manifestation and from healthy donors. MicroRNA-130a was identified by TaqMan Low Density Arrays and verified by quantitative PCR on 144 serum samples (59 multiple myeloma, 55 myeloma with extramedullary disease, 30 healthy donors) in test and validation cohorts as being down-regulated in myeloma patients with extramedullary disease. Circulating microRNA-130a distinguished myeloma patients with extramedullary disease from healthy donors with specificity of 90.0% and sensitivity of 77.1%, patients with extramedullary disease from newly diagnosed multiple myeloma patients with specificity of 77.1% and sensitivity of 34.3% in the test cohort and with specificity of 91.7% and sensitivity of 30.0% in the validation cohort of patients. Circulating microRNA-130a in patients with extramedullary myeloma was associated with bone marrow plasma cells infiltration. Further, microRNA-130a was decreased in bone marrow plasma cells obtained from patients with extramedullary myeloma in comparison to bone marrow plasma cells of myeloma patients without such manifestation, but it was increased in tumor site plasma cells of patients with extramedullary disease compared to bone marrow plasma cells of such patients (p<0.0001). Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma.

Citing Articles

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M Hematol Oncol. 2025; 43(1):e70036.

PMID: 39804194 PMC: 11727818. DOI: 10.1002/hon.70036.

Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.

Vlachova M, Pecinka L, Gregorova J, Moran L, Ruzickova T, Kovacovicova P Sci Rep. 2024; 14(1):18777.

PMID: 39138296 PMC: 11322162. DOI: 10.1038/s41598-024-69408-1.

Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.

Dubaj M, Bigosinski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Malecka-Massalska T Cancers (Basel). 2024; 16(5).

PMID: 38473390 PMC: 10931522. DOI: 10.3390/cancers16051033.

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Vlachova M, Gregorova J, Vychytilova-Faltejskova P, Gablo N, Radova L, Pospisilova L Int J Mol Sci. 2022; 23(23).

PMID: 36499093 PMC: 9741227. DOI: 10.3390/ijms232314765.

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.

Quirico L, Orso F Cancer Drug Resist. 2022; 3(2):117-139.

PMID: 35582611 PMC: 9090592. DOI: 10.20517/cdr.2019.103.

References

Reimers M, Carey V . Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006; 411:119-34. DOI: 10.1016/S0076-6879(06)11008-3. View

Anderson K, Carrasco R . Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-74. DOI: 10.1146/annurev-pathol-011110-130249. View

Vandesompele J, Mestdagh P . Some cautionary notes on the petite "Holy Grail" of molecular diagnostics. Haematologica. 2014; 99(3):401-2. PMC: 3943300. DOI: 10.3324/haematol.2013.103127. View

Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R . Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2012; 54(1):189-91. DOI: 10.3109/10428194.2012.704030. View

Short K, Rajkumar S, Larson D, Buadi F, Hayman S, Dispenzieri A . Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011; 25(6):906-8. PMC: 3736849. DOI: 10.1038/leu.2011.29. View

Larsen M, Hager M, Glenthoj A, Asmar F, Clemmensen S, Mora-Jensen H . miRNA-130a regulates C/EBP-ε expression during granulopoiesis. Blood. 2014; 123(7):1079-89. DOI: 10.1182/blood-2013-08-523233. View

Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S . Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?. Leuk Res. 2009; 33(8):1137-40. DOI: 10.1016/j.leukres.2009.01.036. View

Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P . Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2011; 53(5):920-7. DOI: 10.3109/10428194.2011.634042. View

Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D . Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2014; 136(8):1835-44. PMC: 4382914. DOI: 10.1002/ijc.29199. View

10.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

11.

Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S . Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009; 114(25):e20-6. DOI: 10.1182/blood-2009-08-237495. View

12.

Turchinovich A, Weiz L, Langheinz A, Burwinkel B . Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39(16):7223-33. PMC: 3167594. DOI: 10.1093/nar/gkr254. View

13.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

14.

Chen Y, Gorski D . Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2007; 111(3):1217-26. PMC: 2214763. DOI: 10.1182/blood-2007-07-104133. View

15.

Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J . Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2013; 99(3):511-8. PMC: 3943315. DOI: 10.3324/haematol.2013.093500. View

16.

Rocci A, Hofmeister C, Geyer S, Stiff A, Gambella M, Cascione L . Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014; 28(9):1922-6. PMC: 4155011. DOI: 10.1038/leu.2014.155. View

17.

Kovaleva V, Mora R, Park Y, Plass C, Chiramel A, Bartenschlager R . miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 2012; 72(7):1763-72. DOI: 10.1158/0008-5472.CAN-11-3671. View

18.

Oriol A . Multiple myeloma with extramedullary disease. Adv Ther. 2011; 28 Suppl 7:1-6. DOI: 10.1007/s12325-011-0079-0. View

19.

Turchinovich A, Weiz L, Burwinkel B . Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012; 37(11):460-5. DOI: 10.1016/j.tibs.2012.08.003. View

20.

Jones C, Zabolotskaya M, King A, Stewart H, Horne G, Chevassut T . Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012; 107(12):1987-96. PMC: 3516695. DOI: 10.1038/bjc.2012.525. View